

Bioinformatics: Introduction and Methods


Le Zhang

Computer Science Department, Southwest University









TAACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 CCTAACCCCTAACCCCTAACCCCTAACCCCTAACCC
 CCCTAACCCCTAACCCCTAACCCCTAACCCCTAAC
 AACCCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCAACCCCAACCCCAACCCCAAC
 CTACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCTAACCCCTAACCCCTAACCCCTAA



Transcriptome Analysis with noncoding RNAs



Le Zhang, Ph. D.

Computer Science Department
Southwest University










TAACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 CCTAACCCCTAACCCCTAACCCCTAACCCCTAACCC
 CCTAACCCCTAACCCCTAACCCCTAACCCCTAAC
 AACCCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCAACCCCAACCCCAACCCCAAC
 CTACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCTAACCCCTAACCCCTAACCCCTAA



Unit 1: From Information to Knowledge

Le Zhang, Ph. D.
 Computer Science Department
 Southwest University






(Sequencing) **Data**


	B	C	D	E	F
1	gene	nsc1	nsc1 SE	nsc2	nsc2 SE
2	brain protein	18.9574	3.79952	21.5848	3.02241
3	Cluster Incl AV1	110.513	7.84626	114.894	7.95669
4	Cluster Incl AIE	235.873	35.6748	210.349	27.612
5	Cluster Incl AV3	47.4605	3.94976	29.6941	3.6586
6	Cluster Incl AV1	28.4527	3.74512	15.2986	3.62097
7	Cluster Incl AV1	80.302	6.45368	107.23	8.09591
8	Cluster Incl AV3	40.8113	5.13418	54.0635	3.18591
9	Cluster Incl AI1	68.1437	3.63392	58.635	5.50994

(Expression) **Information**




(Biological) **Knowledge**

Differentially Expression Calling




Pathway




- Functional assignment
- Pathway Enrichment
- Biological Processes

Clustering/Classifying





	B	C	D	E	F
1	gene	nsc1	nsc1 SE	nsc2	nsc2 SE
2	brain protein	18.9574	3.79952	21.5848	3.02241
3	Cluster Incl AW1	110.513	7.84625	114.894	7.95669
4	Cluster Incl AI6	235.873	35.6748	210.349	27.612
5	Cluster Incl AV3	47.4605	3.94976	29.6941	3.6586
6	Cluster Incl AV1	28.4627	3.74512	15.2986	3.62097
7	Cluster Incl AV1	80.302	6.46368	107.23	8.09591
8	Cluster Incl AV3	40.8113	5.13418	54.0835	3.18591
9	Cluster Incl AI1	53.1437	3.63392	58.635	5.50994

(Expression) Information




(Figure Source: <http://ocw.mit.edu/OcwWeb/Economics/14-30Spring-2006/CourseHome/index.htm>)

Statistical Learning-guided Mining



(Modified from Srinivasan Parthasarathy, Ohio State Univ)



(Prior) biological knowledge


(Domain Knowledge)



Data




Model/Algorithm



Parameters

- the transcriptome



(Modified from <http://www.slideshare.net/mateongenaert/05-mestdagh>)

A **non-coding RNA (ncRNA)** is any RNA molecule that could function without being translated into a protein.

The DNA sequence from which a non-coding RNA is transcribed as the end product is often called an RNA gene or **non-coding RNA gene**.

Early discovered ncRNAs are mostly housekeeping

- “Assist” in translation in a necessary, but passive roles
- Constitutively expressed
- Include
 - rRNA
 - tRNA
 - snRNA
 - snoRNA
 - tmRNA
 - telomerase RNA
 - ...

Recently discovered regulatory ncRNAs since 2000

- actively regulate gene transcription and translation
- are involved in various gene regulations through multiple mechanisms
- Many have specific expression patterns
- are widely encoded in the genome
 - The ENCODE (ENCyclopedia Of DNA Elements) pilot project suggested that over 90% of the human genome may be represented in primary transcripts.
 - Over 95% of all transcripts are noncoding. Some estimate the number of ncRNAs to be ~30,000.



THE DARK GENOME

Since the publication of the human genome sequence in 2001, scientists have found that the so-called junk DNA that lies between genes actually carries out many important functions.

(<http://www.sciencemag.org/site/special/insights2010/>)

Representative Regulatory Mechanisms of ncRNAs


Mechanism	Orgnism	Example
Transcriptional repression	Several organisms	Riboswitches
Post-transcriptional regulation	Mouse	miR-196
Translational repression	<i>E. coli</i>	DicF
Translational activation	<i>E. coli</i>	RprA
DNA methylation	<i>Arabidopsis</i>	miRNA
DNA demethylation	Human	KHPS1a
Modification of the histone proteins	<i>Arabidopsis</i>	ncRNA
Regulation of chromatin structure	Yeast	ncRNA
Regulation of mRNA stability	Mouse	Makorin1-p1
Dosage compensation	<i>Drosophila</i>	roX1/roX2
Genomic imprinting	Human	AIR
X chromosome inactivation	Human	XIST
X chromosome activation	Human	TSIX

Table 4 ncRNAs regulate various physiological and pathological events

Event	Organism	Example
Normal events		
Embryo development,	human	Let-7, miRNAs
Cell differentiation	human	NRSE, miR-143
Cell proliferation	<i>Drosophila</i>	Bantam
Regulation of apoptosis	human	ADAPT33
Fat metabolism	<i>Drosophila</i>	Mir-14
Modulation of behaviour	mouse	Bc1
Formation of photoreceptors	rat	TUG1
Regulation of insulin secretion	mouse	miR-375
Regulation of protein localization	<i>Drosophila</i>	hsr
Disease events		
Breast cancer	human	BC200
Colon cancer	human	miR-143, miR-145
Prostate cancer	human	PCGEM1
Lung cancer	human	Let-7
Liver cancer	rat	H19
Myeloid leukemia	mouse	HIS-1
B-CLL	human	miR-15a, miR-16a
B-cell neoplasia	human	BCMS
Angelman syndrome	human	UBE3A/SNURF-SNRPN
Beckwith-Wiedemann Syndrome	human	LIT1
Schizophrenia and bipolar	human	DISC2
Spinocerebellar ataxia	human	SCA8
Prader-Willi syndrome	human	ZNF127AS
Alzheimer's disease	human	BC200
Psoriasis	human	PRINS
Russel-Silver syndrome	human	MESTIT1

microRNA (miRNA)

- single-stranded RNAs of 21-23 (or some say 20-25) nt RNAs with regulatory functions when associated with a protein complex.
- In plants miRNAs can silence gene activity via destruction of homologous mRNA or blocking its translation. In animals, miRNAs inhibit translation by binding with imperfect homology to the 3' untranslated region of mRNA.



Cancer type*	MiRNA profiling data	Significance	Refs
Chronic lymphocytic leukaemia	A unique signature of 13 genes associated with prognostic factors (ZAP70 and IgVH mutation status) and progression (time from diagnosis to therapy)	MiRNAs as diagnostic markers (the identification of two categories of patients)	49,35
Lung adenocarcinoma	Molecular signatures that differ with tumour histology; miRNA profiles correlated with survival (<i>miR-155</i> and <i>let-7</i>)	MiRNAs as prognostic and diagnostic markers	53
Breast carcinoma	MiRNA expression correlates with specific pathological features	MiRNAs as prognostic markers	50
Endocrine pancreatic tumours	A signature that distinguishes endocrine from acinar tumours; the overexpression of <i>miR-21</i> is strongly associated with both a high Ki67 proliferation index and the presence of liver metastases	MiRNAs as diagnostic and prognostic markers	54
Hepatocellular carcinoma	MiRNA expression correlated with differentiation	MiRNAs as prognostic markers	52
Papillary thyroid carcinoma	MiRNA upregulation (for example, <i>miR-221</i> and <i>miR-222</i>) in tumoral cells and normal cells adjacent to tumours, but not in normal thyroids without cancers	MiRNAs probably involved in cancer initiation	37 114
Glioblastoma	A specific signature compared with normal tissues	MiRNAs as diagnostic markers	51
Human cancers	MiRNA-expression profiles accurately classify cancers; an miRNA classifier classes poorly differentiated samples better than a messenger RNA classifier	MiRNAs as diagnostic markers	41
Human solid cancers	Common signature for distinct types of solid carcinomas	Specific miRNAs are involved in common molecular pathways	47

*Only data from microarray studies reporting results on human primary tumours were included in this table. IgV_H, immunoglobulin heavy-chain variable-region, MiRNA, microRNA, ZAP70, 70 kDa zeta-associated protein.


(Source: *Nat Rev Cancer* 6, 857)

Generic Name	Originator	Status	Pharmacology	Target	Indication
SPC-3649	Santaris Pharma	Phase I	MicroRNA inhibitor	microRNA 122	Infection, hepatitis-C virus Hypercholesterolaemia
antagomirs, Alnylam	Alnylam	Preclinical	MicroRNA inhibitor	Unspecified	Unspecified
anti-inflammatory mi- croRNA,Reg	Alnylam*	Preclinical	MicroRNA inhibitor	Unspecified	Unspecified
anticancer microRNA, Regulus	Alnylam*	Preclinical	MicroRNA inhibitor	Unspecified	Unspecified
anti-miR-122 oligo, Regulus	Alnylam*	Preclinical	MicroRNA inhibitor	microRNA 122	Infection, hepatitis-C virus
miRNA inhibitors, Mi- ragen	Miragen Therapeutics	Preclinical	MicroRNA inhibitor	microRNA 208a	Heart failure
miRNA mimetics, Mi- ragen	Miragen Therapeutics	Preclinical	MicroRNA stimulant	Unspecified	Heart failure
prostate cancer miRNAs, Mirna	Mirna Therapeutics	Preclinical	MicroRNA stimulant	Unspecified	Cancer, prostate
AML miRNA therapy, Mirna	Mirna Therapeutics	Preclinical	MicroRNA stimulant	Unspecified	Cancer, leukaemia, acute mye- logenous
nsclc miRNA therapy, Mirna	Mirna Therapeutics	Preclinical	MicroRNA stimulant	microRNA let-7a-1	Cancer, lung, non-small cell
herpes virus therapy, Rosetta	Rosetta Genomics	Preclinical	MicroRNA inhibitor	Unspecified	Infection, Epstein-Barr virus Infection, herpes simplex virus
miR-34a mimetics, Rosetta	Rosetta Genomics	Preclinical	MicroRNA stimulant p53 stimulant Apoptosis agonist	microRNA 34a tumour protein p53	Cancer, liver
hepatitis-C therapy, Rosetta	Rosetta Genomics	Preclinical	MicroRNA inhibitor	Unspecified	Infection, hepatitis-C virus
HIV therapy, Rosetta	Rosetta Genomics	Preclinical	MicroRNA inhibitor	Unspecified	Infection, HIV/AIDS




*Alnylam/Isis Pharmaceuticals joint-venture

(http://www.pharmaprojects.com/therapy_analysis/microRNA-0808-therapeutictarget.html)

Xist : Beyond “small” ncRNA



Xist – X inactive-specific transcript




(Avner *et al.*, 2001)

SCA8:

Long ncRNA in Human Disease

- SCA8 is mutated in one form of spinal cerebella ataxia



(Nemes, J. P. *et al.* 2000)

Long ncRNAs

- Estimated ~2000+ in human.
- Some, but not all, are mRNA-like, with Poly(A) tails.
- Most have unknown function. Many may function via *cis* or *trans* antisense pairing.
 - Dosage compensation (e.g. XIST)
 - Neuron development (e.g. SCA8)
 - Genetic imprinting (e.g. IGF/H19)
 - Post-transcriptional regulation
 - mRNA degradation or stabilization
 - Translational regulation
 - Modulate protein function by directly binding to the protein


How many non-coding transcripts?

What are the functional roles of those ncRNAs?

Identification



(Source: www.lkalop.com)



(Source: www.lemondrop.com/2009/01/22/certain-facial-features-found-to-create-a-feeling-of-trust/) The Boston Globe

Features ~ property of an entity

Sequence features only


Mechanism neutral: works for both long and small ncRNAs

Accurate and Fast

SVM classifier

- SVM – support vector machine


Separate transformed data with a hyper plane in a high-dimensional space



- Kernel function – Radial Basis Function(RBF)


- Grid-search to select proper values of parameter

Sequence features





Feature Selection

Purpose: Choose the best feature set in term of accuracy, speed, and computing space



Find The Optimal Subset






Complete Search: Breadth First

The breadth-first traversal of all variables


$$\binom{n}{k} = \frac{n!}{k!(n-k)!}$$

$$\binom{n}{1} = \binom{n}{2} = \dots = \binom{n}{n-1} = \binom{n}{n}$$



Heuristic Search: Sequential Forward Selection

Features added greedily until the addition of further features does not increase the overall performance.




Random Search: Simulated Annealing


adding or removing features based on an “annealing-like” probability

not reach the optimal solution

Continue training with certain probability



1. Determine an annealing schedule $T(i)$
2. Create an initial solution $Y(0)$
3. While $T(i) > T_{\text{MIN}}$
 - 3a. Generate a new solution $Y(i+1)$ which is a neighbor of $Y(i)$
 - 3b. Compute $\Delta E = - [J(Y(i+1)) - J(Y(i))]$
 - 3b. If $\Delta E < 0$
 - then
always accept the move from $Y(i)$ to $Y(i+1)$
 - else
accept the move with probability $P = \exp(-\Delta E/T(i))$



Initialized feature set

- Properties of entity
- Speculate based on existed knowledge
- Certain statistic established by predecessors
- The data that is thought to be relevant



(Prior) biological knowledge
[Domain Knowledge]



Data



Model/Algorithm



Parameters

Sequence Compositions

e.g. frequency of k-mer

Sequence domains

e.g. known binding motif

(Predicted) Secondary Structure

e.g. folding energy (MFE)

(Conceptually) Translational Product

e.g. ORF length

Homologous


e.g. # of BLASTX hits

60+ features

Fine-tune with Breadth First Searching

11 features

Sequential Forward Selection



Coverage

ORF Integrity

LOG-ODD score



of BLASTX hits

Hit Score

Frame Score

(Conceptually) Translated Product

Coverage

$$\text{Coverage}(S) = \frac{L_{ORF} - (L_{mismatch} + 2 * L_{frameshift})}{\text{Total Length}}$$


ORF Integrity

indicates whether the predicted ORF begins with a start codon and ends with an in-frame stop codon

ATG CCG GCT TAC CAC TCT TCT CTC ATG GAT CCT GAT ACC AAA TAG
M P A Y E S S L M D P D Y K *

LOG-ODD score

indicator of the quality of a predicted ORF. The higher the score, the better the quality of the ORF



(Nucleic Acids Res. 35:W345)

Homologous

of BLASTX hits

A true protein-coding transcript is likely to have more hits with known proteins than a non-coding transcript does

Hit Score

For a true protein-coding transcript, the hits are also likely to have higher quality

$$S_i = \text{mean}_j \{-\log_{10} E_{ij}\}, \quad i \in [0,1,2]$$
$$\text{HIT SCORE} = \text{mean}_{i \in \{0,1,2\}} \{S_i\} = \frac{\sum_{i=0}^2 S_i}{3},$$

Frame Score

For a true protein-coding transcript, most of the hits are likely to reside within one frame, whereas for a true non-coding transcript, even if it matches certain known protein sequence segments by chance, these chance hits are likely to scatter in any of the three frames

$$\text{FRAME SCORE} = \text{variance}_{i \in \{0,1,2\}} \{S_i\} = \frac{\sum_{i=0}^2 (S_i - \bar{S})^2}{2}$$

Coverage


of BLASTX hits

ORF Integrity

Hit Score

LOG-ODD score

Frame Score




<http://cpc.cbi.pku.edu.cn>



<http://cpc.cbi.pku.edu.cn>

Coding Potential Calculator




(Nucleic Acids Res. 35:W345)



<http://cpc.cbi.pku.edu.cn>

Gene Regulation	Function of ncRNA	H Van Baken <i>et al.</i> , PLoS Biology , 2010
	Long ncRNA	H Jia <i>et al.</i> , RNA , 2010 T G Belard <i>et al.</i> , Neuron , 2011 I Ulitsky <i>et al.</i> , Cell , 2011 R S Young <i>et al.</i> , Genome Biol Evol , 2012
	Short Peptide	X Yan <i>et al.</i> , Genome Res , 2011
Stem Cell	Self-Renewal	J S Mohamed <i>et al.</i> , RNA , 2010
	Neuron development	S Y Ng <i>et al.</i> , EMBO Journal , 2011 32 million
Disease	Heart diseases	J H Lee <i>et al.</i> , Circ Res , 2011 from 50000+
	Cancer Marker	B P Mello <i>et al.</i> , Nucleic Acid Res , 2009 around the
	Tumor mechanism	A T Ahira <i>et al.</i> , Molecular Cancer , 2011 R J Flockhart <i>et al.</i> , Genome Res , 2012
Evolution	New genes	D Rose <i>et al.</i> , JBioinform Compt Bio. , 2008 J F Sousa <i>et al.</i> , PLoS One , 2010
	Function divergence of duplicated genes	J T Wang <i>et al.</i> , BMC Genomics , 2012

sequences
users
world



How many non-coding transcripts?

What are the functional roles of those ncRNAs?

microRNA (miRNA)

- single-stranded RNAs of 21-23 (or some say 20-25) bp RNAs with regulatory functions when associated with a protein complex.
- In plants miRNAs can silence gene activity via destruction of homologous mRNA or blocking its translation. In animals, miRNAs inhibit translation by binding with imperfect homology to the 3' untranslated region of mRNA.

Table 4.2 Computational algorithms for microRNA target prediction


Name of the software	URL of availability	Supported organism(s)	Reference(s)
TargetScan, miRanda, miRBase	http://genes.mit.edu/targetscan/	Vertebrates	Lewis <i>et al.</i> , 2003, 2005
A miRanda	http://www.microrna.org/	Flies, vertebrates	Enright <i>et al.</i> , 2003, John <i>et al.</i> , 2004
DIANA-microT	http://diana.pcbi.upenn.edu/DIANA-microT/	Vertebrates	Kiriakidou <i>et al.</i> , 2004
RNAhybrid	http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/	Flies	Rehmsmeier <i>et al.</i> , 2004
GUUGle	http://bibiserv.techfak.uni-bielefeld.de/guugle/	Flies	Gerlach <i>et al.</i> , 2006
PicTar	http://pictar.bio.nyu.edu/	Nematodes, flies, vertebrates	Grun <i>et al.</i> , 2005, Krek <i>et al.</i> , 2005, Lall <i>et al.</i> , 2006
MicroInspector	http://mima.imbb.forth.gr/microinspector/	Any	Rusinov <i>et al.</i> , 2005
B MovingTargets	Available by request on DVD	Flies	Burgler <i>et al.</i> , 2005
FastCompare	http://tavazoielab.princeton.edu/mirnas/	Nematodes, flies	Chan <i>et al.</i> , 2005
miRU	http://bioinfo3.noble.org/miRNA/miRU.htm	Plants	Zhang 2005
TargetBoost	https://demo1.interagon.com/demo/	Nematodes, flies	Saetrom <i>et al.</i> , 2006
rna22	http://cbcsrv.watson.ibm.com/rna22.html	Nematodes, flies, vertebrates	Miranda <i>et al.</i> , 2006
miTarget	http://cbit.snu.ac.kr/~miTarget/	Any	Kim <i>et al.</i> , 2006

(Source: *Methods Enzymol.* 427:65)


Target mRNAs from loci unrelated to miRNA genes

(Source: *Cell* 116:281)

- the transcriptome



A GENE REGULATORY NETWORK



YGG 01-0083


(Modified from public.ornl.gov/site/gallery/highres/REGNET.jpg)



- Differentially expressed genes
- Co-expressed genes



Data Mining: Differentially Expression Calling

- Identify the genes with **biological-significant difference** in expression levels across samples
- Differences in expression values can result from many non-biological sources (e.g. experiment error/bias)
 - The ‘real’ differences are the differences that can **NOT** be explained by the various errors introduced during the experimental phase






- **Random errors** arise from random fluctuations in the measurements
- It could be reduced by repeating experiment many times (and get a mean value)
- Random errors could be modeled statistically by **variance**.

Condition 1





Condition 2



Distribution of expression index for gene g, condition 2


Distribution of differential expression statistic






Statistical calling

1. Select a **statistic** which takes the variance into account, and will rank the genes in order of supporting strength for “differential expression”.
2. Derive the p-value for each gene, based on the **NULL distribution** of the statistic.
3. Choose a **critical-value** for the gene with p-value less than which being called as “**being statistically significant**”.




Student's *t*-distribution




Source: projectile.sv.cmu.edu/research/public/talks/t-test.htm

- The t-test assesses whether the means of two groups are **statistically different** from each other
 - Take the **variance** into account through Standard Error (SE)
- Need to estimate the SE correctly
 - But the correct estimation depends on **prior distribution** (Normal) as well as **the number of replicates** (>10)

Model the data in RNA-Seq



Patcher 2011, arXiv:1104.3889 [q-bio.GN]




(Genome Biology 14:R95)

METHOD

Open Access

Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data

Franck Rapaport¹, Raya Khanin¹, Yupu Liang¹, Mono Pirun¹, Azra Krek¹, Paul Zumbo^{2,3}, Christopher E Mason^{2,3}, Nicholas D Socci¹ and Doron Betel^{3,4*}




Evaluation	Cuffdiff	DESeq	edgeR	limmaVoom	PoissonSeq	baySeq
Normalization and clustering	All methods performed equally well					
DE detection accuracy measured by AUC at increasing qRT-PCR cutoff	Decreasing	Consistent	Consistent	Decreasing	Increases up to log expression change ≤ 2.0	Consistent
Null model type I error	High number of FPs	Low number of FPs	Low number of FPs	Low Number of FPs	Low number of FPs	Low number of FPs
Signal-to-noise vs <i>P</i> value correlation for genes detected in one condition	Poor	Poor	Poor	Good	Moderate	Good
Support for multi-factored experiments	No	Yes	Yes	Yes	No	No
Support DE detection without replicated samples	Yes	Yes	Yes	No	Yes	No
Detection of differential isoforms	Yes	No	No	No	No	No
Runtime for experiments with three to five replicates on a 12 dual-core 3.33 GHz, 100 G RAM server	Hours	Minutes	Minutes	Minutes	Seconds	Hours

AUC, area under curve; DE, differential expression; FP, false positive.

		Hypothesis truth?	
		H_1 (active)	H_0 (inactive)
Output of statistical test	Reject H_0 (active)	Hit	Type I error
	Accept H_0 (inactive)	Type II error	Correct rejection

FUNCTIONAL MAGNETIC RESONANCE IMAGING, Figure 12.2 © 2004 Sinauer Associates, Inc.

- Type I Error (False Positive): **rejecting** the null hypothesis when **it is true**
- Type II Error (False Negative): **accepting** the null hypothesis when **it is false**



Multiple Testing Issue

- If more than one test is made, then the collective FP value is **greater** than in the single-test
 - That is, **overall Type I error** increases
- E.g: you checked your RNA-Seq data and found 20 significantly different genes with a 0.05 threshold on each gene, then what is the chance that you making at least one error in overall?

- $\text{Pr}(\text{making a mistake}) = 0.05$
- $\text{Pr}(\text{not making a mistake}) = 1 - 0.05 = 0.95$
- $\text{Pr}(\text{not making any mistake}) = 0.95_{20} = 0.358$
- $\text{Pr}(\text{making at least one mistake}) = 1 - 0.358 = 0.642$

➔ There is a 64.2% chance of making at least one mistake

Multiple Testing Issue

Bonferroni Correction

- Most straightforward and plain
- For n hypothesis tests, only call p-values less than α/n as “being significant”.
 - Or, adjust the raw p-value as $\min(n \cdot p, 1)$
- For example, if we want to have an experiment wide Type I error rate of 0.05 when we comparing 30000 genes, we’d need p-values less than $0.05/30000 = 1.67 \times 10^{-6}$ so that the gene(s) could be called as “being significant”

Type I (false positive) error rates

- Family-wise Error Rate

$$\text{FWER} = p(V \geq 1)$$

- Per-family Error Rate

$$\text{PFER} = E(V)$$

- Per-comparison Error Rate

$$\text{PCER} = E(V)/m$$

False Discovery Rate

$$\text{FDR} = E(V/R)$$

- False Positive Rate

$$\text{FPR} = E(V/m_0)$$

Proportion of false positives among the genes that are flagged as differentially expressed.

	#not rejected	#rejected	totals
#trueH	U	V (False Positive)	m ₀
#non-true H	T (False Negative)	S	m ₁
totals	m-R	R	m





q-value


- **q-value** is an measure of False Discovery Rate (FDR)
 - Proposed by Storey *et al.* in 2002 and tuned for microarray analysis
- The **q-value** for a particular gene g is the **expected proportion** of false positives incurred when calling that gene g “significant”.
- In contrast, the **p-value** for a particular gene g is the **probability that a randomly generated expression profile** would be as or more extremely differentially expressed.

- Differentially expressed genes
- Co-expressed genes

Clustering: Group cases (genes/samples) with similar expression pattern/levels (**Unsupervised learning**)

- Hierarchical Cluster, k-mean Cluster, Self-Organizing Maps (SOM), etc





(*Nature Genetics* 42:1113)

Distance measurement: how “similar” between two genes’ profile

Euclidean distance
(Absolution distance)


$$s(x_1, x_2) = \sqrt{\sum_{k=1}^K (x_{1k} - x_{2k})^2}$$

Pearson distance
(Correlation distance)

$$s(x_1, x_2) = \frac{\sum_{k=1}^K (x_{1k} - \bar{x}_1)(x_{2k} - \bar{x}_2)}{\sqrt{\sum_{k=1}^K (x_{1k} - \bar{x}_1)^2 \sum_{k=1}^K (x_{2k} - \bar{x}_2)^2}}$$


Pearson Distance:

- red-blue: .006
- red-gray: .768
- blue-gray: .7101





Eucl. Distance:

- red-blue: 9.45
- red-gray: 10.26
- blue-gray: 3.29










TAACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 CCTAACCCCTAACCCCTAACCCCTAACCCCTAACCC
 CCCTAACCCCTAACCCCTAACCCCTAACCCCTAAC
 AACCCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCAACCCCAACCCCAACCCCAAC
 CTACCCTAACCCCTAACCCCTAACCCCTAACCCCTA
 ACCCTAACCCCTAACCCCTAACCCCTAACCCCTAA




Unit 4:

Computer Lab: Feature selection and Cluster analysis

Le Zhang, Ph. D.
 Computer Science Department
 Southwest University



Find The Optimal Subset



The way to find the optimal subset (M. Dash and H. Liu 1997)

Introduction Of Heuristic Search

- **SFS , Sequential Forward Selection**
Set of variables starts from an empty set, each time we select a variable to join the subset and the optimal solution in the evaluation is selected. Each time select a optimal variable to join, a simple greedy algorithm.
- **SBS , Sequential Backward Selection**
Set of variables starts from an set which has all variables ,each time we remove a variable from the subset and the optimal solution in the evaluation is selected.
- **BDS , Bidirectional Search**
Using a sequence forward selection (SFS) starts from the empty set, while using the sequence backward selection (SBS) to start the search from the universal set, when the two are the same, stop the search.

Introduction Of Heuristic Search

- **LRS , Plus-L Minus-R Selection**

Starts from the empty set, each time join L variables, and then remove R variables, the optimal solution in the evaluation is selected. ($L > R$)

Starts from the universal set, each time remove R variables, and then join L variables, the optimal solution in the evaluation is selected. ($L < R$)

- **Sequential Floating Selection**

Sequential Floating Selection is from the Plus-L Minus-R Selection , the differs is : the L and R is not fixed ,it will changing.




SFS

Set of variables starts from an empty set, each time we select a variable to join the subset and the optimal solution in the evaluation is selected. Each time select a optimal variable to join, a simple greedy algorithm.




SBS


Set of variables starts from an set which has all variables ,each time we remove a variable from the subset and the optimal solution in the evaluation is selected.



	all	delete OF	提高 (%)
positive accuracy	96.77419	96.80099	0.026796
negative accuracy	94.63674	95.2545	0.617753
total accuracy	96.09479	96.31242	0.217628
调和平均值	95.36019	96.02152	0.661323



	* all	delete ORF	提高 (%)
positive accu	96.80099	97.1580817	0.357092
negetive accu	95.254497	95.0397577	-0.21474
totle accurac	96.312417	96.481683	0.169266
调和平均值	96.021517	96.087246	0.065729



	* * all	FRAME score	提高 (%)
positive accuracy	97.15808171	96.414763	-0.743319
negative accuracy	95.03975767	95.544363	0.50460498
total accuracy	96.48168299	96.143151	-0.3385322
调和平均值	96.08724605	95.977589	-0.1096567

What is clustering

- Cluster analysis or clustering is the task of grouping a set of objects in such a way that objects in the same group (called a cluster) are more similar (in some sense or another) to each other than to those in other groups (clusters).

--from wikipedia

Distance

- Manhattan distance $(1) \sum |x_i - y_i|$
- Euclidean distance $(2) \sqrt{\sum (x_i - y_i)^2}$
- Minkowski distance $(p) \left[\sum |x_i - y_i|^p \right]^{1/p}$
- Chebyshev distance $(\infty) \max |x_i - y_i|$
- Mahalanobis distance $(\Sigma^{-1}) \sqrt{(x - y)^T \Sigma^{-1} (x - y)}$
- Lance and Williams distance $(\alpha, \beta) \sum \frac{|x_i - y_i|}{\alpha + \beta}$

Change to distance

- Using R
- **dist(x, method = "euclidean", diag = FALSE, upper = FALSE, p=2)**
- **x** a numeric matrix, data frame or "dist" object.
- **method** the distance measure to be used. This must be one of "euclidean", "maximum", "manhattan", "canberra", "binary" or "minkowski". Any unambiguous substring can be given.
- **diag** logical value indicating whether the diagonal of the distance matrix should be printed by print.dist.
- **upper** logical value indicating whether the upper triangle of the distance matrix should be printed by print.dist.
- **p** The power of the Minkowski distance.

Hierarchical clustering method

- Single linkage method $\min\{ \quad , \quad \}$
- Complete linkage method $m \{ \quad , \quad \}$
- Median method $\text{---} (\quad)$
- Average linkage method $\text{---} \quad \text{---}$
- Centroid method $\text{---} \quad \text{---} \quad \text{---}$
- Ward method $= \text{---} \quad \text{---} \quad \text{---}$

hclust

- `hclust(d, method = "complete", members = NULL)`
- `d` a dissimilarity structure as produced by `dist`.
- `method` the agglomeration method to be used. This should be (an unambiguous abbreviation of) one of "ward", "single", "complete", "average", "mcquitty", "median" or "centroid".

Reference

- 统计建模与 R 软件
- <http://www.cnblogs.com/xiangshancuizhu/archive/2012/03/12/2392360.html>
- http://en.wikipedia.org/wiki/Feature_selection
- http://en.wikipedia.org/wiki/Cluster_analysis
- <http://www.biostars.org/p/14156/>

Background

- High-throughput sequencing technology is rapidly becoming the standard method for measuring RNA expression levels (aka RNA-seq).
- One of the main goals of these experiments is **to identify the differentially expressed genes** in two or more conditions.

Differential gene expression analysis

- 3 steps:
 - 1. Normalization of counts
 - 2. parameter estimation of the statistical model
 - 3. Test for differential gene expression

Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data

Franck Rapaport¹, Raya Khanin¹, Yupu Liang¹, Mono Pirun¹, Azra Krek¹, Paul Zumbo^{2,3}, Christopher E Mason^{2,3}, Nicholas D Socci¹ and Doron Betel^{3,4*}

Goal : Comparison of different analysis methods for RNA-seq data from different perspectives.

Such as, Cuffdiff, edgeR, DESeq, PoissonSeq, baySeq, and limma.

Datasets for Research

They used two benchmark datasets:

- 1 The first is the **Sequencing Quality Control (SEQC) dataset**, which includes replicated samples of the human whole body reference RNA and human brain reference RNA along with RNA spike-in controls.
- 2 The second dataset is **RNA-seq data** from biological replicates of three cell lines that were characterized as part of the **ENCODE project**.

The measures of their analysis

- The analysis in this paper focused on a number of measures that are most relevant for detection of differential gene expression from RNA-seq data
- i) normalization of count data;
- ii) sensitivity and specificity of DE detection;
- iii) performance on the subset of genes that are expressed in one condition but have no detectable expression in the other condition;
- iv) the effects of reduced sequencing depth and number of replicates on the detection of differential expression.

Normalized counts by log expression correlation




Figure 1 RMSD correlation between qRT-PCR and RNA-seq log₂ expression changes computed by each method. Overall, there is good concordance between log₂ values derived from the DE methods and the experimental values derived from qRT-PCR measures. Upper quartile normalization implemented in baySeq package is least correlated with qRT-PCR values. DE, differential expression; RMSD, root-mean-square deviation.

Differential expression analysis






Figure 2 Differential expression analysis using qRT-PCR validated gene set. **(a)** ROC analysis was performed using a qRT-PCR \log_2 expression change threshold of 0.5. The results show a slight advantage for DESeq and edgeR in detection accuracy. **(b)** At increasing \log_2 expression ratios (incremented by 0.1), representing a more stringent cutoff for differential expression, the performances of the Cuffdiff and limma methods gradually reduce whereas PoissonSeq performance increases. AUC, area under the curve.

		Truth ("Gold standard")		
		Positive	Negative	
Test Outcome	Positive	True Positive (hit)	False Positive (false alarm)	Positive predictive value (PPV) = Precision = $TP / (TP+FP)$
	Negative	False Negative (miss)	True Negative (correct rejection)	Negative predictive value (NPV) = $TN / (TN+FN)$
		Sensitivity = Recall = $TP / (TP+FN)$	Specificity = $TN / (TN+FP)$	Accuracy = $(TP+TN) / \text{total}$
		False negative rate (β) = Type II error = 1- sensitivity = $FN / (TP+FN)$	False positive rate (α) = Type I error = 1- specificity = $FP / (TN+FP)$	False discovery rate (FDR) = 1 - precision = $FP / (TP+FP)$


Null model evaluation of type I error



Impact of sequencing depth and number of replicate samples on DE analysis



(a)



(b)

Replicate 2rep 3rep

Conclusion

- 1 In most benchmarks **Cuffdiff performed less favorably**
 - ✓ **with** a higher number of **false positives**
 - ✓ **without** any increase in **sensitivity**.
- 2 Our results conclusively demonstrate that the **addition of replicate samples** provides substantially greater detection power of DE than increased sequence depth.
 - **Hence, including more replicate samples in RNA-seq experiments is always to be preferred over increasing the number of sequenced reads.**

Bioinformatics: Introduction and Methods

Computer Science Department, Southwest University

Thank you

